Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.

被引：0
|
作者：
Vassilev, Zdravko
Fan, Xiaozhou
Ostojic, Helene
Xu, Julie
Barzi, Afsaneh
机构：
[1] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[2] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [11] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [12] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Lindsay, Sheila
    Nalla, Sneha
    Schwartz, Gabriel
    Whitman, Julia
    Zendejas, Patricia
    Zhang Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [13] Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Spadi, Rosella
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17): : 1609 - 1618
  • [14] Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
    Yu Sunakawa
    Hironaga Satak
    Wataru Ichikawa
    World Journal of Gastrointestinal Oncology, 2018, (12) : 528 - 531
  • [15] Modified FOLFOXIRI plus bevacizumab as a salvage regimen for patients with refractory metastatic colorectal cancer
    Ou, Yuxuan
    Zhang, Jianwei
    Cai, Yue
    Hu, Huabin
    Xie, Xiaoyu
    Ling, Jiayu
    Deng, Yanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [16] FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
    Antoniotti, Carlotta
    Vetere, Guglielmo
    Cremolini, Chiara
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [17] Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
    Bond, M. J. G.
    van Smeden, M.
    Degeling, K.
    Cremolini, C.
    Schmoll, H. J. E-V.
    Rossini, D.
    Ibach, S.
    Koopman, M.
    Punt, C. J. A.
    May, A. M.
    Kwakman, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S438 - S438
  • [18] Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
    Sunakawa, Yu
    Satake, Hironaga
    Ichikawa, Wataru
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 10 (12) : 528 - 531
  • [19] Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)
    Bullock, K. E.
    Hurwitz, H. I.
    Uronis, H. E.
    Morse, M. A.
    Blobe, G. C.
    Hsu, S. D.
    Zafar, S. Y.
    Nixon, A. B.
    Howard, L. A.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [20] Exploratory analysis of circulating pro- and antiangiogenie factors ini metastatic colorectal cancer (mCRC) patients, treated with GONO-FOLFOXIRI plus bevacizumab (BV)
    Cremolini, C.
    Loupakis, F.
    Salvatore, L.
    Schirripa, M.
    Fioravanti, A.
    Orlandi, P.
    Di Desidero, T.
    Danesi, R.
    Falcone, A.
    Bocci, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345